TScan Therapeutics, Inc. - TCRX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 5.4% | 3,014,267 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 5.4% | 3,014,267 | View |
| May 15, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 3.3% | 1,868,548 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 3.3% | 1,868,548 | View |
| May 15, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 1.0% | 560,400 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 1.0% | 560,400 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 8.7% | 4,882,815 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 9.99% | 5,578,288 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF INC/IL | 9.99% | 5,578,288 | View |
| May 15, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 9.99% | 5,578,288 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.